SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 3 Issue: Supplement 1 Special Issue

Osteosarcoma of rib treated with regorafenib: a case report

Orkun Sakar(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı)0000-0002-1624-4339
Cemre Uçaryılmaz(KOÇ ÜNİVERSİTESİ)0000-0002-5758-1120
Ahmet Bilgehan Şahin(TIP FAKÜLTESİ)0000-0002-7846-0870
Türkkan Evrensel(TIP FAKÜLTESİ)0000-0002-9732-5340
Cengiz Gebitekin(TIP FAKÜLTESİ)0000-0001-8718-9499
Pages
—
Publication Date
2021-03-07
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we presented a rare case of osteosarcoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints.
📊
Key Findings & Data:Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints.
💡
Conclusion & Impact:Here, we presented a rare case of osteosarcoma.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:oncology · osteosarcoma of rib · regorafenib

Abstract

Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints. Here, we presented a rare case of osteosarcoma.

🔖

Cite This Article

Sakar, O., Uçaryılmaz, C., Şahin, A. B., Evrensel, T., Gebitekin, C. (2021). Osteosarcoma of rib treated with regorafenib: a case report. Turkish Journal of Internal Medicine, Volume: 3 Issue: Supplement 1 Special Issue. https://doi.org/10.46310/tjim.875951

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Mirabello L, Troisi R J, Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43. doi: 10.1002/cncr.24121.
  2. Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.
  3. Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3.
  4. Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.